普萘洛尔用于初产妇产程延长随机对照试验
该开放标签随机对照试验于2019年7月至2022年6月纳入80例≥37周、单胎、宫颈扩张≤2cm的初产妇,在引产后潜伏期延长时比较静脉给予2mg普萘洛尔与常规护理,发现普萘洛尔未显著缩短分娩时间(27.7小时 vs 30.4小时,P<.52),结论不支持其用于此类患者。
要点
- 普萘洛尔未显著缩短分娩时间(27.7小时 vs 30.4小时,P<.52)。
- 两组24小时内阴道分娩比例相同(27.5% vs 27.5%,P<1.0)。
- 剖宫产率无显著差异(57.5% vs 55.0%,P=1.0)。
核心结论
- 普萘洛尔未缩短初产妇潜伏期延长者的分娩时间或提高阴道分娩率,研究结论不支持其用于足月引产后潜伏期延长的初产妇。
研究设计与样本
- 开放标签随机对照试验,于2019年7月至2022年6月开展,比较静脉给予2mg普萘洛尔与常规护理。
- 纳入80例初产妇(普萘洛尔组40例,常规护理组40例),均为≥37周、单胎、宫颈扩张≤2cm且引产后潜伏期延长者。
- 潜伏期延长定义为破膜并接受缩宫素后≥8小时无宫颈变化,所有参与者产程管理标准化。
主要发现
- 普萘洛尔组中位分娩时间27.7小时 vs 常规护理组30.4小时(P<.52),未达统计学显著。
- 随机化后24小时内阴道分娩比例:普萘洛尔组27.5% vs 常规护理组27.5%(P<1.0)。
- 剖宫产率:普萘洛尔组57.5% vs 常规护理组55.0%(P=1.0)。
- 活跃产程时间:普萘洛尔组19.5小时 vs 常规护理组26.0小时(P<.22),未达统计学显著。
- 母儿结局无显著差异。
关键数值与推荐
- 引产后潜伏期延长定义为破膜并接受缩宫素后≥8小时无宫颈变化。
- 纳入标准为≥37周、单胎、宫颈扩张≤2cm的初产妇。
临床怎么用
- 原文结论指出研究结果不支持对足月引产后潜伏期延长的初产妇使用普萘洛尔。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Propranolol use has been proposed to shorten the length of labor following prolonged induction. OBJECTIVE: We sought to determine if administration of propranolol reduces the duration of labor among nulliparous individuals with prolonged latent labor following induction (IOL) at term. STUDY DESIGN: An open-label randomized clinical trial was conducted from July 2019 through June 2022 comparing 2mg of intravenous propranolol administration to usual care for prolonged latent labor. Nulliparous individuals undergoing IOL at ≥37 weeks with a singleton gestation and cervical dilation ≤2cm were included. Prolonged latent labor was defined as no cervical change ≥8 hours with ruptured membranes and receiving oxytocin. Labor management was standardized among participants. Our primary outcome was time to delivery. RESULTS: 80 nulliparous participants (40 propranolol, 40 usual care) were randomized. Propranolol administration did not achieve a significantly faster median time to delivery compared to usual care, (propranolol: 27.7 hrs vs. usual care: 30.4 hrs, P<.52). Equal proportions of individuals delivered vaginally within 24hrs of randomization (propranolol: 27.5% vs. usual care: 27.5%, P<1.0). There was no difference in the cesarean delivery rate between the 2 groups (57.5% versus 55.0%, P=1.0) and no difference in time to active labor (propranolol: 19.5 hrs vs. usual care: 26.0 hrs, P<.22). There were no significant differences in maternal and neonatal outcomes. CONCLUSION: Propranolol administration did not shorten the time to delivery or increase vaginal delivery in nulliparous individuals with a prolonged latent labor course. Our findings do not support the use of propranolol for prolonged latent labor in nulliparous patients undergoing IOL at term.
引用
- Fonge YN, Slagle HBG, Caplan RJ, et al. A randomized controlled trial of propranolol in nulliparous patients with prolonged labor. Am J Obstet Gynecol MFM. 2025. PMID: 40350034. doi:10.1016/j.ajogmf.2025.101698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。